Clinical Trial

SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors

Study acronym: SABR PRIMER
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The study is being done to determine if stereotactic ablative radiotherapy (SABR) can control tumour growth for patients with metastatic breast cancer. Secondary objectives will be overall survival, progression-free survival and time to switch of next line of systemic therapy. Radiation-related adverse events will be assess, with a specific focus on dermatitis, lymphedema and brachial plexopathy. The exploratory objective is to correlate toxicities and outcomes with peripheral blood biomarkers and circulating tumor DNA to potentially help predict responses in future patients receiving combined therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-15.
Trial Details
NCT Number NCT06937281
Lead Sponsor British Columbia Cancer Agency
Conditions Breast Cancer, Metastases
Enrollment 40 participants
Start Date 2025-07-01
Primary Completion 2029-06-30 (estimated)
Study Completion 2030-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-24